(E)-(3-isopropoxyprop-1-enyl)cyclohexane | 1041865-71-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-(3-isopropoxyprop-1-enyl)cyclohexane
• 英文别名: [(E)-3-propan-2-yloxyprop-1-enyl]cyclohexane
• CAS: 1041865-71-7
• 化学式: C₁₂H₂₂O
• 分子量: 182.306
• InChiKey: QPIRSLHUZSMEAT-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己基丙二醇 、 异丙醇 在 silver trifluoromethanesulfonate 作用下， 反应 2.0h， 以42%的产率得到(E)-(3-isopropoxyprop-1-enyl)cyclohexane
  参考文献：
  名称：

  金催化的烯类分子间加氢烷氧基化反应；加氢烷氧基化和加氢胺化机理的差异

  摘要：

  在ClAuPPh 3 / AgOTf催化剂的存在下，在没有溶剂的情况下，各种各样的醇2与各种丙二烯1反应，生成烯丙基醚3。与通过手性烯丙基的高手性面选择性产生相应手性烯丙基胺的加氢胺化相反，在加氢烷氧基化中未观察到手性的转移，这表明金催化加氢烷氧基化的机理与加氢胺化不同。

  DOI：

  10.1016/j.tetlet.2008.05.152

文献信息

• Ether compounds for treatment of complement mediated disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10550140B2

  公开（公告）日：2020-02-04

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本发明提供了包含式 I 或其药学上可接受的盐或组合物（其中 A 基上的 R12 或 R13 是醚（R32））的补体因子 D 抑制剂的化合物、使用方法和制造工艺。本文所述的抑制剂以因子 D 为靶点，在替代补体途径的早期和关键点抑制或调节补体级联，并降低因子 D 调节经典和凝集素补体途径的能力。本文所述的因子 D 抑制剂能够减少补体的过度活化，而补体的过度活化与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20190048033A1

  公开（公告）日：2019-02-14

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.